首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   600550篇
  免费   33201篇
  国内免费   693篇
耳鼻咽喉   7591篇
儿科学   18844篇
妇产科学   13578篇
基础医学   102211篇
口腔科学   13146篇
临床医学   55592篇
内科学   109739篇
皮肤病学   12711篇
神经病学   41022篇
特种医学   22590篇
外国民族医学   53篇
外科学   90030篇
综合类   8425篇
一般理论   197篇
预防医学   43854篇
眼科学   13685篇
药学   46422篇
  1篇
中国医学   1164篇
肿瘤学   33589篇
  2021年   4851篇
  2019年   5851篇
  2018年   8023篇
  2017年   5835篇
  2016年   6630篇
  2015年   7396篇
  2014年   10175篇
  2013年   14383篇
  2012年   21792篇
  2011年   23868篇
  2010年   13455篇
  2009年   11908篇
  2008年   20868篇
  2007年   22797篇
  2006年   21908篇
  2005年   21166篇
  2004年   20315篇
  2003年   19340篇
  2002年   18444篇
  2001年   22957篇
  2000年   23280篇
  1999年   19309篇
  1998年   5621篇
  1997年   4533篇
  1996年   4487篇
  1995年   4513篇
  1992年   14632篇
  1991年   16011篇
  1990年   16121篇
  1989年   15772篇
  1988年   14443篇
  1987年   14316篇
  1986年   13294篇
  1985年   12822篇
  1984年   9557篇
  1983年   8131篇
  1982年   4394篇
  1979年   9011篇
  1978年   6471篇
  1977年   5223篇
  1976年   5548篇
  1975年   6654篇
  1974年   7448篇
  1973年   7191篇
  1972年   6624篇
  1971年   6338篇
  1970年   5907篇
  1969年   5482篇
  1968年   5179篇
  1967年   4633篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectiveTo determine prognostic factors and survival patterns for different treatment modalities for nasal cavity (NC) and paranasal sinus (PS) mucosal melanoma (MM).MethodsPatients from 1973 to 2013 were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and multivariable cox proportional hazard modeling were used for survival analyses.ResultsOf 928 cases of mucosal melanoma (NC = 632, PS = 302), increasing age (Hazard Ratio [HR]:1.05/year, p < 0.001), T4 tumors (HR: 1.81, p = 0.02), N1 status (HR: 6.61, p < 0.001), and PS disease (HR: 1.50, p < 0.001) were associated with worse survival. Median survival length was lower for PS versus NC (16 versus 26 months, p < 0.001). Surgery and surgery + radiation therapy (RT) improved survival over non-treatment or RT alone (p < 0.001). Adding RT to surgery did not yield a survival difference compared with surgery alone (p = 0.43). Five-year survival rates for surgery and surgery + RT were similar, at 27.7% and 25.1% (p = 0.43).ConclusionSurgery increased survival significantly over RT alone. RT following surgical resection did not improve survival.  相似文献   
2.
3.
4.
European Journal of Epidemiology - With the rising use of machine learning for healthcare applications, practitioners are increasingly confronted with the limitations of prediction models that are...  相似文献   
5.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
6.
7.
8.

Background

During coronavirus disease 2019 (COVID-19)–related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called SABR-BRIDGE. This study presents the preliminary surgical and pathological results.

Methods

Eligible participants from four institutions (three in Canada and one in the United States) had early-stage presumed or biopsy-proven lung malignancy that would normally be surgically resected. SABR was delivered using standard institutional guidelines, with surgery >3 months following SABR with standardized pathologic assessment. Pathological complete response (pCR) was defined as absence of viable cancer. Major pathologic response (MPR) was defined as ≤10% viable tissue.

Results

Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3–4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). SABR was well-tolerated, with one grade 5 toxicity (death 10 days after SABR with COVID-19) and five grade 2–3 toxicities. Following SABR, 26 patients underwent resection thus far (13 pending surgery). Median time-to-surgery was 4.5 months post-SABR (range, 2–17.5 months). Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirteen patients (50%) had pCR and 19 (73%) had MPR. Rates of pCR trended higher in patients operated on at earlier time points (75% if within 3 months, 50% if 3–6 months, and 33% if ≥6 months; p = .069). In the exploratory best-case scenario analysis, pCR rate does not exceed 82%.

Conclusions

The SABR-BRIDGE approach allowed for delivery of treatment during a period of operating room closure and was well-tolerated. Even in the best-case scenario, pCR rate does not exceed 82%.  相似文献   
9.
The UK islet allotransplant program is nationally funded to deliver one or two transplants over 12 months to individuals with type 1 diabetes and recurrent severe hypoglycemia. Analyses were undertaken 10 years after program inception to evaluate associations between transplanted mass; single versus two transplants; time between two transplants and graft survival (stimulated C-peptide >50 pmol/L) and function. In total, 84 islet transplant recipients were studied. Uninterrupted graft survival over 12 months was attained in 23 (68%) single and 47 (94%) (p = .002) two transplant recipients (separated by [median (IQR)] 6 (3–8) months). 64% recipients of one or two transplants with uninterrupted function at 12 months sustained graft function at 6 years. Total transplanted mass was associated with Mixed Meal Tolerance Test stimulated C-peptide at 12 months (p < .01). Despite 1.9-fold greater transplanted mass in recipients of two versus one islet infusion (12 218 [9291–15 417] vs. 6442 [5156–7639] IEQ/kg; p < .0001), stimulated C-peptide was not significantly higher. Shorter time between transplants was associated with greater insulin dose reduction at 12 months (beta ?0.35; p = .02). Graft survival over the first 12 months was greater in recipients of two versus one islet transplant in the UK program, although function at 1 and 6 years was comparable. Minimizing the interval between 2 islet infusions may maximize cumulative impact on graft function.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号